ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print December 1, 2008
Eur Respir J 2008, doi:10.1183/09031936.00107408
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
33/3/574    most recent
09031936.00107408v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ayers, L.
Right arrow Articles by Kohler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ayers, L.
Right arrow Articles by Kohler, M.


ORIGINAL ARTICLE

Circulating cell-derived microparticles in patients with minimally-symptomatic obstructive sleep apnoea

L. Ayers 1, B. Ferry 1, S. Craig 2, D. Nicoll 2, J.R. Stradling 2, M. Kohler 3*

1 Dept of Clinical Immunology, Churchill Hospital, Oxford, UK
2 Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK
3 Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK; and Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland

* To whom correspondence should be addressed. E-mail: Malcolm.K{at}bluewin.ch.


   Abstract

Moderate-severe obstructive sleep apnoea (OSA) has been associated with several pro-atherogenic mechanisms and increased cardiovascular risk but it is not known if minimally-symptomatic OSA has similar effects. Circulating cell-derived microparticles have been shown to have pro-inflammatory, pro-coagulant and endothelial function impairing effects, as well as to predict subclinical atherosclerosis and cardiovascular risk.

In 57 patients with minimally-symptomatic OSA, and 15 closely-matched control subjects without OSA, AnnexinV+, platelet-, leukocyte- and endothelial-cell derived microparticles were measured by flow-cytometry.

In patients with OSA, levels of AnnexinV+ microparticles were significantly elevated, 2586 (1566–3964) µl-1 compared to control subjects, 1206 (474–2501) µl-1 (medians and interquartile range, p=0.007). Levels of platelet-derived and leukocyte-derived microparticles were also significantly higher in patients with OSA 2267 (1102–3592) µl-1 and 20 (14–31) µl-1 respectively, compared to control subjects, 925 (328–2068) µl-1 and 15 (5–23) µl-1 respectively (p=0.009 and p=0.02 respectively). Endothelial-cell-derived microparticle levels were similar in patients with OSA, 13 (8–25) µl-1, compared to control subjects, 11 (6–17) µl-1 (p=0.21).

In patients with minimally-symptomatic OSA, levels of AnnexinV+, platelet- and leukocyte-derived microparticles are elevated when compared to closely-matched control subjects without OSA. These findings suggest that these patients may be at increased cardiovascular risk, despite being minimally-symptomatic.

Keywords:  Atherosclerosis, cardiovascular risk, microparticles, obstructive sleep apnoea







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the European Respiratory Society.